{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:29:34Z","timestamp":1761092974317,"version":"build-2065373602"},"reference-count":20,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":3729,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2001,11]]},"abstract":"<jats:p>Olanzapine, a serotonin\u2010dopamine\u2010receptor antagonist, is an atypical antipsychotic agent used to treat schizophrenia and other psychotic disorders. It is preferred over older antipsychotics because of its relatively low frequency of sedation, orthostatic hypotension, extrapyramidal symptoms, and anticholinergic side effects. A 45\u2010year\u2010old man with well\u2010controlled type 2 diabetes mellitus experienced an abrupt worsening of his diabetes after 3 years of olanzapine therapy. His hemoglobin A<jats:sub>1c<\/jats:sub> (HbA<jats:sub>1c<\/jats:sub>) level rose from a baseline of 5.9\u20136.2% to 12.5%. Discontinuation of olanzapine by means of a 3\u2010month taper resulted in a reduction in HbA<jats:sub>1c<\/jats:sub> to pretreatment levels. Although cases of olanzapine\u2010induced hyperglycemia have been documented in the literature, this complication has not been reported in a patient maintained on therapy for this duration. Clinicians should be aware of this possible complication in patients receiving long\u2010term olanzapine therapy.<\/jats:p>","DOI":"10.1592\/phco.21.17.1444.34423","type":"journal-article","created":{"date-parts":[[2004,6,8]],"date-time":"2004-06-08T12:06:03Z","timestamp":1086696363000},"page":"1444-1447","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Dramatic Worsening of Type 2 Diabetes Mellitus Due to Olanzapine After 3 Years of Therapy"],"prefix":"10.1002","volume":"21","author":[{"given":"Christopher I.","family":"Bechara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer D.","family":"Goldman\u2010Levine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/55.10.1003"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v59n1208a"},{"volume-title":"Zyprexa (olanzapine) package insert. Indianapolis","year":"1986","author":"Eli Lilly and Company","key":"e_1_2_1_4_2"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(98)00100-0"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0033-3182(99)71210-7"},{"key":"e_1_2_1_7_2","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1176\/ajp.156.9.1471","article-title":"Olanzapine\u2010induced ketoacidosis with diabetes mellitus [letter]","volume":"156","author":"Lindenmayer J.P.","year":"1999","journal-title":"Am J Psychiatry"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.22.6.1002"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.156.6.970"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.19327"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v59n1208c"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.10178"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-5491.2000.00296.x"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.10280"},{"volume-title":"Zyprexa (olanzapine) data on file","year":"2001","author":"Eli Lilly and Company","key":"e_1_2_1_15_2"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.3109\/10401239809148817"},{"key":"e_1_2_1_17_2","first-page":"40","article-title":"Side effect profiles of new antipsychotic agents","volume":"11","author":"Casey D.E.","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-440X(96)90054-1"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1995.tb00541.x"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)80086-7"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.21.17.1444.34423","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.21.17.1444.34423","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T09:38:35Z","timestamp":1761039515000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.21.17.1444.34423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,11]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2001,11]]}},"alternative-id":["10.1592\/phco.21.17.1444.34423"],"URL":"https:\/\/doi.org\/10.1592\/phco.21.17.1444.34423","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2001,11]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}